The World Health Organization’s (WHO) declaration of the Bundibugyo virus outbreak in the Democratic Republic of the Congo and Uganda as a Public Health Emergency of International Concern is not a prediction of another Covid-19 outbreak.
It is something more precise: a warning that high-consequence spillovers are now occurring against a backdrop of ecological instability, fragile health systems and weakening global health institutions.
As of the latest WHO briefing, 51 cases had been confirmed in the DRC, two confirmed cases had been reported in Kampala, and almost 600 suspected cases and 139 suspected deaths were under investigation.
WHO assessed the national and regional risk as high, while the global risk remains low. That distinction matters.
Ebola is not an airborne respiratory virus like influenza or SARS-CoV-2. It spreads mainly through direct contact with blood, body fluids, contaminated materials, unsafe healthcare exposure or burial practices. It is controllable but only when detection, isolation, contact tracing, infection prevention and community trust happen early.
The scientific concern is that this outbreak is caused by Bundibugyo virus, a distinct orthoebolavirus. Much of the world’s Ebola countermeasure portfolio was built around Zaire ebolavirus, particularly after the 2014-2016 West African epidemic. The best-established licensed vaccine and monoclonal antibody platforms target Zaire ebolavirus.
For Bundibugyo virus, WHO has stated that there are currently no approved strain-specific vaccines or therapeutics. This is not a technical footnote. The viral surface glycoprotein, the major target of neutralising antibodies, differs sufficiently across ebolaviruses that cross-protection cannot be assumed. Some cross-reactive immunity may be biologically possible, but in outbreak control, uncertainty is not a strategy.
Bundibugyo is therefore both an emergency and a symptom. The broader pattern is now impossible to ignore. Nipah virus continues to cause high-fatality outbreaks in Bangladesh and India, with WHO estimating case fatality rates of 40 to 75 per cent and confirming that human infection can occur through contaminated food, animal exposure or close contact with infected people.
Andes hantavirus recently entered international travel networks through the MV Hondius cruise-ship cluster, reminding us that even infections traditionally seen as geographically restricted can become operationally global when mobility is involved.
H5N1 avian influenza has expanded into mammals, including United States dairy cattle, with Nature studies showing viral RNA and infectious virus in milk, mammary-gland tropism and evidence of cow-to-cow transmission.
These pathogens differ in taxonomy, transmission and epidemic potential. Yet the signal is shared. Land-use change, wildlife disruption, intensive agriculture, climate pressure, urbanisation and global mobility are increasing the number of interfaces at which viruses can test new hosts.
Climate-change modelling has already warned that mammalian range shifts could increase opportunities for cross-species viral transmission. Each spillover is not a pandemic. But each spillover is a biological experiment, giving a pathogen another opportunity to adapt to human or livestock systems.
This is why the current political moment is dangerous. The world is facing more warning shots just as key institutions are being weakened. Science has reported proposed US budget reductions affecting biomedical research and global health programmes, including a 62 per cent reduction to global health programmes in the US State Department request5.
The British Medical Journal (BMJ) has reported that WHO planned to cut its 2026-2027 budget by more than a fifth following US withdrawal and reduced funding from other nations6. A Lancet analysis estimated that USAID-funded programmes helped prevent more than 91 million deaths over two decades and projected that abrupt defunding could lead to more than 14 million additional deaths by 2030.
This is not bureaucracy. It is an outbreak infrastructure. Surveillance officers, field epidemiologists, diagnostic laboratories, genomic sequencing networks, sample-transport systems, emergency operations centres and community-health partnerships are what allow a strange fever cluster to be recognised before it becomes a regional crisis.
If these systems are dismantled, the world will still detect outbreaks but later, with fewer tools, weaker trust and higher mortality.
For Malaysia and Southeast Asia, the lesson is immediate. The risk of Bundibugyo virus importation remains low, but low risk is not the same as no preparedness.
Southeast Asia sits at the intersection of biodiversity, land-use change, dense mobility, intensive farming and climate-sensitive infections. Malaysia has first-hand historical experience with Nipah. The region continues to face dengue expansion, avian influenza threats, zoonotic malaria, bat-borne viruses and repeated outbreak alerts.
Preparedness here should be practical, not performative. Clinicians must be trained to ask travel and exposure histories. Hospitals need clear isolation and referral pathways. Laboratories need safe specimen-handling protocols and rapid molecular testing capacity.
Genomic surveillance must be integrated across human, animal and environmental health. Risk communication must be multilingual, calm and stigma-free. Border screening may have a role, but it cannot substitute for strong local detection and response.
The most important lesson from Ebola, Nipah, Hantavirus, and H5N1 is not that the next pandemic is inevitable. It is that the probability of a dangerous event rises when biological risk increases and institutional readiness declines.
Preparedness is often criticised as expensive until an outbreak escapes; then it becomes the cheapest investment the world failed to make.
The Bundibugyo outbreak will probably be contained if rapid public-health action is sustained. But the warning should not be wasted. In a century defined by ecological disruption and political uncertainty, pandemic preparedness cannot depend on short funding cycles or the priorities of a single country.
WHO, the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), national public-health institutes and regional surveillance networks are not optional accessories. They are the immune system of global health.
Ebola is the warning shot. Nipah, hantavirus and H5N1 are flashing on the same dashboard. The question is whether we strengthen the system now or wait until the next virus finds the weakness we chose to ignore.
Assoc Prof Dr Vinod Balasubramaniam is a molecular virologist and the leader of Infection and Immunity Research Strength at the Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia. Photo courtesy of the author.
- This is the personal opinion of the writer or publication and does not necessarily represent the views of CodeBlue.
